In this study we identify p90RSK as a novel biomarker of cisplatin resistance and demonstrate that dual therapy of p90RSK inhibitor, BI-D1870, with cisplatin is synergistically lethal in high TMEM16A expressing HNSCC cell line models. This evidence concerns the gene RPS6KA1 and head and neck squamous cell carcinoma.